PARIS, FRANCE, 25 July 2024 - Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024. Business highlights U.S. regulatory approvals and launches of Onivyde® (irinotecan) in first-line pancreatic cancer and Iqirvo® (elafibranor) in second-line primary biliary cholangitis, respectively In-licensing of tovorafenib​ outside the U.S.: an attractive addition to our Oncology pipeline Multiple early-stage external-innovation transactions across Oncology and Neuroscience Financial highlights Total-sales growth of 9.5% at CER1, or 8.0% as reported, driven by the performances of Cabometyx® (cabozantinib) and Dysport® (abobotulinumtoxinA), as well as contributions from Bylvay® (odevixibat) and Onivyde Core operating margin of 32.4%, a decline of 1.6% points, driven mainly by enhanced R&D investment. An unchanged IFRS operating margin of 19.2% Upgraded 2024 financial guidance: total-sales growth greater than 7.0% at CER1 (prior guidance: greater than 6.0% at CER1); core operating margin greater than 30.0% of total sales (prior guidance: around 30%) "Our strategic progress was illustrated by strong results in the first half, and we are well placed to deliver continued attractive growth over the medium term", commented David Loew, Chief Executive Officer, Ipsen. "Across Oncology, Rare Disease and Neuroscience, we now have a comprehensive portfolio of medicines, with additional launches in key indications this year. Onivyde and Iqirvo are now being rolled out and we are confident in our ability to deliver on their potential. I was also delighted by a further expansion of our pipeline, including the recent in-licensing of the late-stage asset, tovorafenib, in pediatric Oncology. "Over the remainder of the year, we will remain sharply focused on the launches and commercial execution, as well as further opportunities to expand the pipeline. We have a clear and focused strategic roadmap and a culture of excellence in execution to enable us to make a real difference for patients and society." Extract of consolidated results for H1 2024 and H1 20232:         H1 2024 H1 2023 % change   €m €m Actual CER3 Total Sales   1,659.3 1,536.6 8.0% 9.5% Core Operating Income   538.0 523.2 2.8%   Core operating margin   32.4% 34.0% -1.6% pts   Core Consolidated Net Profit   399.4 393.0 1.6%   Core earnings per share (fully diluted)   €4.78 ...